Efficacy and safety of pioglitazone added to alogliptin in Japanese patients with type 2 diabetes mellitus: a multicentre, randomized, double‐blind, parallel‐group, comparative study

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 12, 2015-12 ,pp. : 1198-1201

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of teneligliptin, a dipeptidyl peptidase‐4 inhibitor, combined with metformin in Korean patients with type 2 diabetes mellitus: a 16‐week, randomized, double‐blind, placebo‐controlled phase III trial

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 3, 2015-03 ,pp. : 309-312

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study*

By Pratley Richard E.   Reusch Jane E.-B.   Fleck Penny R.   Wilson Craig A.   Mekki Qais  

Current Medical Research and Opinion, Vol. 25, Iss. 10, 2009-10 ,pp. : 2361-2371

Informa Healthcare

Access to resources Recommend Favorite

Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double‐blind placebo‐controlled 102‐week trial

By  

DIABETIC MEDICINE, Vol. 32, Iss. 4, 2015-04 ,pp. : 531-541

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial

By Barzilai Nir   Guo Hua   Mahoney Erin M.   Caporossi Suzanne   Golm Gregory T.   Langdon Ronald B.   Williams-Herman Debora   Kaufman Keith D.   Amatruda John M.   Goldstein Barry J.   Steinberg Helmut  

Current Medical Research and Opinion, Vol. 27, Iss. 5, 2011-05 ,pp. : 1049-1058

Informa Healthcare

Access to resources Recommend Favorite